These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1312304)

  • 1. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates.
    Azzi A; Ciappi S; Zakvrzewska K; Morfini M; Mariani G; Mannucci PM
    Am J Hematol; 1992 Mar; 39(3):228-30. PubMed ID: 1312304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.
    Santagostino E; Mannucci PM; Gringeri A; Azzi A; Morfini M; Musso R; Santoro R; Schiavoni M
    Transfusion; 1997 May; 37(5):517-22. PubMed ID: 9149778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of human parvovirus B19 and TT virus in a group of young haemophiliacs in South Africa.
    Rubinstein R; Karabus CD; Smuts H; Kolia F; Van Rensburg EJ
    Haemophilia; 2000 Mar; 6(2):93-7. PubMed ID: 10781195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parvovirus B19 transmission by a high-purity factor VIII concentrate.
    Wu CG; Mason B; Jong J; Erdman D; McKernan L; Oakley M; Soucie M; Evatt B; Yu MY
    Transfusion; 2005 Jun; 45(6):1003-10. PubMed ID: 15935000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient hypoplastic anemia caused by primary human parvovirus B19 infection in a previously untreated patient with hemophilia transfused with a plasma-derived, monoclonal antibody-purified factor VIII concentrate.
    Matsui H; Sugimoto M; Tsuji S; Shima M; Giddings J; Yoshioka A
    J Pediatr Hematol Oncol; 1999; 21(1):74-6. PubMed ID: 10029819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parvovirus B19 transmission by heat-treated clotting factor concentrates.
    Blümel J; Schmidt I; Effenberger W; Seitz H; Willkommen H; Brackmann HH; Löwer J; Eis-Hübinger AM
    Transfusion; 2002 Nov; 42(11):1473-81. PubMed ID: 12421221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates.
    Lefrère JJ; Mariotti M; Thauvin M
    Lancet; 1994 Jan; 343(8891):211-2. PubMed ID: 7904670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group.
    Mannucci PM; Gdovin S; Gringeri A; Colombo M; Mele A; Schinaia N; Ciavarella N; Emerson SU; Purcell RH
    Ann Intern Med; 1994 Jan; 120(1):1-7. PubMed ID: 7504424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Severe parvovirus B19 infection in an immunocompetent child with hemophilia A].
    Coumau E; Peynet J; Harzic M; Béal G; Castaigne S; Leverger G; Foucaud P
    Arch Pediatr; 1996 Jan; 3(1):35-9. PubMed ID: 8745824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transmission of human parvovirus B19 by coagulation factor concentrates.
    Williams MD; Cohen BJ; Beddall AC; Pasi KJ; Mortimer PP; Hill FG
    Vox Sang; 1990; 58(3):177-81. PubMed ID: 2160147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates.
    Bartolomei Corsi O; Azzi A; Morfini M; Fanci R; Rossi Ferrini P
    J Med Virol; 1988 Jun; 25(2):165-70. PubMed ID: 2839609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates.
    Mannucci PM
    Vox Sang; 1993; 64(4):197-203. PubMed ID: 8517048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation.
    Soucie JM; Siwak EB; Hooper WC; Evatt BL; Hollinger FB;
    Transfusion; 2004 Aug; 44(8):1179-85. PubMed ID: 15265122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma.
    Koenigbauer UF; Eastlund T; Day JW
    Transfusion; 2000 Oct; 40(10):1203-6. PubMed ID: 11061856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transmission of human parvovirus B19 by plasma derived factor VIII concentrates.
    Laurian Y; Dussaix E; Parquet A; Chalvon-Demersay A; d'Oiron R; Tchernia G
    Nouv Rev Fr Hematol (1978); 1994 Dec; 36(6):449-53. PubMed ID: 7753615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human parvovirus PARV4 in clotting factor VIII concentrates.
    Fryer JF; Hubbard AR; Baylis SA
    Vox Sang; 2007 Nov; 93(4):341-7. PubMed ID: 18070279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prevalence of parvovirus B19 IgG antibodies among Dutch hemophilia patients.
    Mauser-Bunschoten EP; Zaaijer HL; van Drimmelen AA; de Vries S; Roosendaal G; van den Berg HM; Lelie PN
    Vox Sang; 1998; 74(4):225-7. PubMed ID: 9691402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parvovirus B19 infection in patients with hemophilia.
    Ragni MV; Koch WC; Jordan JA
    Transfusion; 1996 Mar; 36(3):238-41. PubMed ID: 8604509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.